Increasing Medical Marijuana and Cannabidiol Research

This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act to facilitate medical research. It also directs multiple health agencies to develop research methods using real-world evidence for medical marijuana and hemp-derived CBD products, and tasks White House legislative staff with working Congress to update statutory definitions for hemp-derived cannabinoids.

Federal Register Open PDF 90 FR 60541

Impact dates

Date TBD
Attorney General to complete rescheduling rulemaking in most expeditious manner

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

Pharma Agriculture Other industrial

Mechanisms

LicensingProcurement

Role pressure

MixedDomestic producer — Hemp-derived CBD manufacturers face potential new THC limits and ratio requirements; marijuana rescheduling may reduce research barriers but increase FDA oversight
UncertainImporter — Hemp-derived cannabinoid import rules may change with statutory updates; unclear impact on international suppliers
MixedDownstream manufacturer — Full-spectrum CBD products with THC above thresholds will become controlled substances under Section 781, while research expansion may create new product development opportunities

Geographies

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

MMM3MAAPLAppleADMArcher Daniels MidlandBGBungeCATCaterpillarCTVACortevaLLYEli LillyFCXFreeport-McMoRanGEVGE VernovaHONHoneywellJNJJohnson & JohnsonMRKMerckNVSNovartisPFEPfizerSPYSPDR S&P 500 ETFTSNTyson Foods

Confidence: medium · Policy alerts

Key directives

Attorney General shall complete marijuana rescheduling to Schedule III 'in the most expeditious manner'
Deputy Chief of Staff for Legislative Affairs shall work with Congress to update hemp-derived cannabinoid statutory definitions
HHS Secretary, FDA Commissioner, CMS Administrator, and NIH Director shall develop real-world evidence research methods for hemp-derived cannabinoid products
Develop regulatory framework for hemp-derived cannabinoids with THC per serving limits, per container limits, and CBD to THC ratio requirements

Who is ordered

Timeline

Immediate

Attorney General directed to expedite Schedule III rescheduling rulemaking
HHS, FDA, CMS, NIH directed to develop research methods

Near term (90d)

Congressional outreach on hemp-derived cannabinoid statutory updates expected to begin
Interagency consultation on CBD regulatory framework including THC limits

Long term

Potential completion of marijuana rescheduling to Schedule III
Development of real-world evidence research infrastructure
Possible FDA standards of care for medical marijuana and CBD

Risks & tensions

Rescheduling rulemaking already pending with 43,000 public comments and awaiting administrative law hearing; 'expeditious' timeline uncertain given procedural requirements
Congressional action on hemp-derived cannabinoids requires bipartisan cooperation; statutory change not guaranteed
Section 781 of Public Law 119-37 will reclassify some full-spectrum CBD products as marijuana, creating tension with access goals
CBD product mislabeling found in recent studies poses consumer safety risks that research must address
Vulnerable population focus (adolescents, young adults) may conflict with expanded access goals